Cite
HARVARD Citation
Krystal, J. et al. (2022). Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 400 (10369), pp. 2210-2220. [Online].